



Novel Vaccines and Vaccine Technologies for Emerging Infections

Guest Editors:

Prof. Dr. Wangxue Chen

Dr. Xuguang Li

Prof. Dr. Amine A. Kamen

Deadline for manuscript
submissions:

15 October 2024

Message from the Guest Editors

This Special Issue aims to provide a platform for sharing the most recent advances in the development of novel vaccine candidates, platforms, and technologies for combating emerging infections and future pandemics. More specifically, we welcome the contribution of original research articles, reviews, and commentaries that address the following topics:

- New vaccine platforms, technologies, and adjuvants;
- Universal vaccine candidates;
- Mucosal vaccines and vaccination;
- Modular vaccine platforms for rapid biomanufacturing and expedited regulatory approval;
- Vaccines as a tool for antimicrobial resistance;
- AI application in the rapid identification of novel vaccine antigens;
- Immune correlates of vaccine-induced protection;
- Systems immunology and vaccinology;
- Novel in vitro and in vivo assays and models for assessing vaccine-induced immunity and predicting vaccine efficacies;
- Vaccine bioprocess and manufactures.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com